Track PolyPeptide Group AG — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

PolyPeptide Group AG PPGN.SW Open PolyPeptide Group AG in new tab

37.90 CHF
EPS
-0.59
P/B
3.91
ROE
-6.07
Beta
1.02
Target Price
35.75 CHF
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 13, 2026
EPS-0.59
Book Value9.54
Price to Book3.91
Debt/Equity41.50
% Insiders60.524%
Growth
Revenue Growth0.10%
Estimates
Forward P/E33.00
Forward EPS1.13
Target Mean Price35.75

DCF Valuation

Tweak assumptions to recompute fair value for PolyPeptide Group AG (PPGN.SW)
Currency: CHF
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

PolyPeptide Group AG Logo PolyPeptide Group AG Analysis (PPGN.SW)

Switzerland Health Care Official Website Stock

Is PolyPeptide Group AG a good investment? PolyPeptide Group AG (PPGN.SW) is currently trading at 37.90 CHF. Market analysts have a consensus price target of 35.75 CHF. This suggests the asset is currently trading above analyst expectations.

Earnings Schedule: PolyPeptide Group AG is expected to release its next earnings report on Aug. 13, 2026. The market consensus estimate for Forward EPS is 1.13.

Investor FAQ

Does PolyPeptide Group AG pay a dividend?

No, it does not currently pay a dividend.

What asset class is PolyPeptide Group AG?

PolyPeptide Group AG is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 13, 2026. The company currently has a trailing EPS of -0.59.

Company Profile

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, pharmaceutical, and biotech companies. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.

Exchange Ticker
EBS (Ireland) PPGN.SW
Historical Dividends
Year Total Dividends
2022 0.30 CHF

Yearly aggregated dividends

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion